Procaps Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Procaps Group şirketinin kazançları yıllık ortalama -13.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.1% oranında artan oldu. Gelirler yıllık ortalama 4.8% oranında azalan oldu. Procaps Group şirketinin öz sermaye getirisi 135.8% olup, net marjı 12.6% dir.

Anahtar bilgiler

-13.2%

Kazanç büyüme oranı

-13.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	-4.8%
Özkaynak getirisi	135.8%
Net Marj	12.6%
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Procaps Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:9X1 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 23	414	52	179
30 Jun 23	406	67	174
31 Mar 23	408	33	183
31 Dec 22	410	43	185
30 Sep 22	435	60	175
30 Jun 22	431	-73	168
31 Mar 22	418	-67	156
31 Dec 21	410	-101	151
30 Sep 21	401	-119	157
30 Jun 21	374	-9	147
31 Mar 21	342	-18	137
31 Dec 20	331	-10	128
01 Jan 20	325	-17	145

Kaliteli Kazançlar: 9X1 büyük bir tek seferlik kazanç ile $40.5M, 30th September, 2023 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: 9X1 'nin mevcut net kar marjları (12.6%) geçen yılın (13.8%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 9X1 son 5 yılda karlı hale geldi.

Büyüme Hızlandırma: 9X1 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 9X1 geçtiğimiz yıl negatif kazanç büyümesine ( -13.2% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 28.7% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 9X1 'nin Özsermaye Getirisi ( 135.77% ) olağanüstü olsa da, bu ölçüt yüksek borç seviyeleri nedeniyle çarpıktır.

Procaps Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.22 in 3Q 2022)

Procaps Group S.A. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: EPS: US$0.27 (vs US$0.068 loss in 2Q 2022)

Procaps Group S.A. to Report Q2, 2023 Results on Sep 05, 2023

Procaps Group S.A. to Report Q1, 2023 Results on Jun 05, 2023

Full year 2022 earnings released: EPS: US$0.42 (vs US$1.03 loss in FY 2021)

Recent updates

New minor risk - Market cap size

High number of new directors

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 19%

Procaps Group S.A. Announces Resignation of Ruben Minski as Board of Directors

Investor sentiment deteriorates as stock falls 17%

Hoche Partners Raises Concerns on Shareholder Letter Issued by Procaps Group

High number of new directors

Hoche Partners Criticizes Procaps Group's Majority Shareholder for Mismanagement and Rejection of Financial Restructuring Offer

Procaps Group S.A. Announces Board Changes

Procaps Group S.A. announced delayed 20-F filing

Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 21%

Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives

Investor sentiment deteriorates as stock falls 23%

New major risk - Revenue and earnings growth

Hoche Partners Sends a Letter to Procaps Group

Hoche Partners Sends a Letter to Procaps Group

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.22 in 3Q 2022)

Investor sentiment improves as stock rises 26%

Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024

Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024

Procaps Group S.A. to Report Q3, 2023 Results on Nov 14, 2023

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 23%

Procaps Group S.A. Appoints Sandra Sanchez Y Oldenhage as A Director

Investor sentiment deteriorates as stock falls 20%

Second quarter 2023 earnings released: EPS: US$0.27 (vs US$0.068 loss in 2Q 2022)

New major risk - Earnings quality

Procaps Group S.A. to Report Q2, 2023 Results on Sep 05, 2023

Procaps Group S.A., Annual General Meeting, Jun 30, 2023

Procaps Group S.A. to Report Q1, 2023 Results on Jun 05, 2023

Full year 2022 earnings released: EPS: US$0.42 (vs US$1.03 loss in FY 2021)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 25%

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Procaps Group S.A. Announces Board Changes

Procaps Group S.A. (NasdaqGM:PROC) announces an Equity Buyback for 2,000,000 shares, for $5 million.

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Procaps Group Announces Key Changes to the Board of Directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.22 (vs US$1.14 loss in 3Q 2021)

Procaps Group S.A. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.01 loss in 2Q 2021)

Now 20% undervalued after recent price drop

Procaps Group S.A., Annual General Meeting, Jun 28, 2022

Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation.

Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation.

Full year 2021 earnings released: US$1.03 loss per share (vs US$5.22 loss in FY 2020)

Forecast to breakeven in 2022

Now 21% undervalued after recent price drop

Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director

Procaps Group, S.A. (NasdaqGM:PROC) acquired 86,000 sq. ft. Pharmaceutical Production Facility Located in West Palm Beach, Florida from Strides Pharma Inc.

Less than half of directors are independent

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin